T cell and NK cell lymphoproliferative disorders.
This review covers the diagnosis and management of natural killer and peripheral T-cell lymphomas (PTCL). Problems with PTCL include their rarity, representing usually 10-15% of non-Hodgkin's lymphomas in the Western Hemisphere, morphologic heterogeneity, and lack of immunophenotypic markers for clonality. Additionally, their clinical behavior is variable and may not correlate with morphology. Dr. Kinney gives a general overview of the diagnosis of PTCL and NK cell neoplasms. Emphasis will be placed on extranodal T cell and natural killer (NK) cell lymphomas such as hepatosplenic lymphoma, subcutaneous panniculitis-like lymphoma and nasal/nasal type T/NK-cell lymphoma. The use of ALK gene regulation in the classification of anaplastic large cell lymphoma is also reviewed. Dr. Loughran describes current understanding of the pathogenesis of large granular lymphocyte (LGL) leukemia. The discussion focuses on LGL leukemia as an instructive model of dysregulated apoptosis causing both malignant and autoimmune disease. Current management options and mechanisms of therapeutic response are also described. Dr. Greer addresses whether PTCL should be treated differently from the more common diffuse large B cell lymphomas. He discusses the therapeutic options for anaplastic large cell lymphoma (ALCL), from a conservative approach for primary cutaneous ALCL to combination chemotherapy for the highly chemosensitive ALCL expressing anaplastic lymphoma kinase. He reviews therapy options for the extranodal subtypes of PTCL by drawing from series in adults, pediatrics, dermatology, and the Far East.
Greer
J P
JP
H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Kinney
M C
MC
Loughran
T P
TP
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007694:Killer Cells, Natural / Q000473:pathology*; D015458:Leukemia, T-Cell / Q000209:etiology / Q000473:pathology / Q000628:therapy; D016411:Lymphoma, T-Cell, Peripheral / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000473:pathology* / Q000628:therapy; D013601:T-Lymphocytes / Q000473:pathology
D000970:Antineoplastic Agents